crisantaspase recombinant


( Last Updated : July 20, 2022)
Generic Name:
crisantaspase recombinant
Project Status:
Pending
Therapeutic Area:
Acute lymphoblastic leukemia
Call for patient/clinician input open:
Brand Name:
Rylaze
Project Line:
Reimbursement Review
Project Number:
PC0301-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia

Details


Manufacturer Requested Reimbursement Criteria1:
Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Lymphoblastic lymphoma (LBL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Leukemia
Indications:
Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of: Acute lymphoblastic leukemia (ALL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Lymphoblastic lymphoma (LBL) in adults and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.